Market News AIOpen the app

CHRS stock news · Coherus Oncology, Inc.

Stories about Coherus Oncology, Inc. (CHRS) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for CHRS

Follow Coherus Oncology, Inc. (CHRS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CHRS
Free on the App Store and Google Play, or on the web.
  1. Oct 31, 2026, 9:57 AM ET · Market

    H.C. Wainwright started following Coherus Oncology and thinks it's a good buy, setting a target price of $7.00.

    Good for CHRS

    Coherus Oncology received a new Buy rating from H.C. Wainwright, with a $7 share target.

  2. Aug 17, 2026, 5:36 PM ET · Market

    Coherus Oncology, Inc. announces the establishment of a significant definitive agreement (CHRS).

    Neutral

    Coherus Oncology has filed a Form 8-K detailing its entry into a material definitive agreement, which is likely to have a positive impact on its strategic initiatives and financial obligations. This could signal growth opportunities or partnerships that may enhance its market position.